Literature DB >> 526406

Use of labetalol during hypotensive anaesthesia and in the management of phaeochromocytoma.

L Kaufman.   

Abstract

1 The circulatory effects of labetalol have been studied in 88 patients undergoing plastic surgery, 8 patients with carcinoma of the breast, 10 with carcinoma in the head and neck, and in 2 patients with phaeochromocytoma, each anaesthetized twice. 2 The use of labetalol intravenously produced hypotension and a bloodless operating field in patients undergoing plastic surgery and in those undergoing radical surgery for the removal of carcinoma. 3 Two patients with phaeochromocytoma pre-treated with oral labetalol before anaesthesia, had well controlled BPs and heart rates during surgery, although in one instance additional intravenous labetalol was required. 4 Pre-operative preparation of patients with phaeochromocytoma with labetalol seems to be simpler and safer than previous techniques involving drugs with separate alpha- and beta-adrenoceptor-blocking effects.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 526406      PMCID: PMC1429755     

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  6 in total

1.  The effects of labetalol (AH 5158) on adrenergic transmission in the cat spleen.

Authors:  A G Blakeley; R J Summers
Journal:  Br J Pharmacol       Date:  1977-04       Impact factor: 8.739

Review 2.  Pharmacological effects of labetalol in man.

Authors:  D A Richards
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

3.  Pharmacology of AH 5158; a drug which blocks both - and -adrenoceptors.

Authors:  J B Farmer; I Kennedy; G P Levy; R J Marshall
Journal:  Br J Pharmacol       Date:  1972-08       Impact factor: 8.739

4.  Treatment of phaeochromocytoma and of clonidine withdrawal hypertension with labetalol.

Authors:  E A Rosei; J J Brown; A F Lever; A S Robertson; J I Robertson; P M Trust
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

5.  Cardiovascular effects of labetalol during halothane anaesthesia.

Authors:  D B Scott; F P Buckley; G B Drummond; D G Littlewoods; W R Macrae
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

6.  Circulatory effects of labetalol during halothane anaesthesia.

Authors:  D B Scott; F P Buckley; D G Littlewood; W R Macrae; G R Arthur; G B Drummond
Journal:  Anaesthesia       Date:  1978-02       Impact factor: 6.955

  6 in total
  6 in total

1.  Pheochromocytoma--recent advances in diagnosis and treatment.

Authors:  N L Benowitz
Journal:  West J Med       Date:  1988-05

Review 2.  The management of hypertension.

Authors:  B N Prichard; C W Owens
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

3.  Labetalol, an alpha- and beta-adrenoceptor-blocking agent: its use in therapeutics. A summary of the symposium.

Authors:  B N Prichard; D A Richards
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

4.  Treatment of hypertension with labetalol in neurosurgical practice. Influence of labetalol on cerebral perfusion pressure in dogs without and with intracranial mass lesions.

Authors:  C Puchstein; H van Aken; J Hidding; C Anger; P Lawin
Journal:  Acta Neurochir (Wien)       Date:  1983       Impact factor: 2.216

Review 5.  Combined alpha- and beta-receptor inhibition in the treatment of hypertension.

Authors:  B N Prichard
Journal:  Drugs       Date:  1984       Impact factor: 9.546

6.  Retrospective evaluation of labetalol as antihypertensive agent in dogs.

Authors:  Francesco Zublena; Chiara De Gennaro; Federico Corletto
Journal:  BMC Vet Res       Date:  2020-07-24       Impact factor: 2.741

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.